


-55-

CLAIMS

1. A compound of formula



or a pharmaceutically acceptable salt thereof,

5

or a prodrug thereof,

wherein n is an integer of from 1 to 4.

2. A compound according to Claim 1 wherein n is an integer of from 2 to 4.
3. A compound according to Claim 1 wherein the compound is a compound of Formula I.
- 10 4. A compound according to Claim 1 and selected from: add name for
 (1 α ,6 α ,8 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid;
 (2-Aminomethyl-octahydro-inden-2-yl)-acetic acid; (2-Aminomethyl-
 octahydro-pentalen-2-yl)-acetic acid; (2-Aminomethyl-octahydro-
 pentalen-2-yl)-acetic acid; (3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic
 15 acid; (3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid; and
 (2-Aminomethyl-octahydro-inden-2-yl)-acetic acid.
5. A compound according to Claim 1 and selected from:
 (1 α ,5 β)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
 (1 α ,5 β)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
 20 (1 α ,5 β)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
 (1 α ,6 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
 (1 α ,7 β)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,

- (1 α ,5 β)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1 α ,5 β)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
(1 α ,5 β)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1 α ,6 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
5 (1 α ,7 β)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
(1 α ,3 α ,5 α)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1 α ,3 α ,5 α)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1 α ,6 α ,8 α)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1 α ,7 α ,9 α)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
10 (1 α ,3 β ,5 α)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1 α ,3 β ,5 α)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
(1 α ,3 β ,5 α)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1 α ,6 α ,8 β)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1 α ,7 α ,9 β)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
15 ((1R,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
20 ((1R,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((3 α R,5R,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α R,5S,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
25 ((3 α S,5S,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α S,5R,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((2R,4 α S,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α S,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α R,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
30 ((2R,4 α R,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,

-57-

- ((2R,4 α S,9 α R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
((2S,4 α S,9 α R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
5 ((2S,4 α R,9 α S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
((2R,4 α R,9 α S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
10 ((1R,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1R,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
15 ((1S,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((3 α R,5R,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α R,5S,7 α R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3 α S,5S,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
20 ((3 α S,5R,7 α S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((2R,4 α R,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α S,8 α R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4 α R,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4 α S,8 α S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
25 ((2R,4 α R,9 α R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
((2S,4 α R,9 α R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
((2S,4 α S,9 α S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid, and
30

-58-

((2R,4 α S,9 α S)-2-Aminomethyl-decahydro-benzocyclohepten-2-yl)-acetic acid.

6. A compound according to Claim 1 named (1 α ,3 α ,5 α)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid.
- 5 7. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.
8. A method for treating epilepsy comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in
10 need of said treatment.
9. A method for treating faintness attacks, hypokinesia, and cranial disorders comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
10. A method for treating neurodegenerative disorders comprising
15 administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
11. A method for treating depression comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
- 20 12. A method for treating anxiety comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
13. A method for treating panic comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in
25 need of said treatment.

-59-

14. A method for treating pain comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
- 5 15. A method for treating neuropathological disorders comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.
16. A method for treating premenstrual syndrome comprising administering a therapeutically effective amount of a compound according to Claim 1 to a mammal in need of said treatment.